Proteomic analysis reveals that treatment with tocotrienols reverses the effect of H2O2 exposure on peroxiredoxin expression in human lymphocytes from young and old individuals

Dahlan, Hasnizawati Mohamed; Karsani, Saiful Anuar; Rahman, Mariati Abdul; Hamid, Noor Aini Abdul; Top, A. Gapor Mat; Ngah, Wan Zurinah Wan

doi:10.1016/j.jnutbio.2011.03.018

Cited by 21 publications

(16 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was observed that peroxiredoxin 6 and proteasome activator complex subunit 1 are downregulated in human lymphocytes treated with H 2 O 2 (27). The fact that we observe the opposite effect might be due to the specific action of dopamine agonists on dopaminergic receptors, therefore excluding nonspecific effect due to generic oxidative stress.…”

Section: Discussionmentioning

confidence: 45%

Dopaminergic therapies modulate the T‐CELL proteome of patients with Parkinson's disease

et al. 2012

View full text Add to dashboard Cite

SummaryDopamine receptor agonists and L-dihydroxyphenylalanine (L-DOPA) counteract dopamine loss in the striatum and are therefore used in the treatment of Parkinson's disease (PD). T-Lymphocytes express some features of the dopaminergic system, and their function or activation might be regulated by dopaminergic treatments. Two-dimensional electrophoresis of total protein extract from T-lymphocytes was performed to identify therapy-induced proteome changes in T-cells of 17 patients with PD. Specific protein level alterations were further validated by Western blotting. Of 17 enrolled patients, 11 were treated with different doses of L-DOPA; in this group, we found that the levels of two spots, corresponding to ATP synthase subunit b and proteasome subunit b type-2, correlated linearly with the L-DOPA daily dose. Moreover, we identified seven proteins (prolidase, actin-related protein 2, F-actin-capping protein subunit b, tropomyosin a-3 chain, proteasome activator complex subunit 1, peroxiredoxin 6, and a glyceraldehyde-3-phosphate dehydrogenase isoform) whose levels were significantly different in patients treated with dopamine agonists. These findings demonstrate that dopaminergic stimulation has important effects on T-cell proteome in patients under long-term treatment. Therefore, therapies acting on the dopaminergic system may have additional effects on the immune system. 2012 IUBMB IUBMB Life, 64(10): 846-852, 2012

show abstract

Section: Discussionmentioning

confidence: 45%

Dopaminergic therapies modulate the T‐CELL proteome of patients with Parkinson's disease

et al. 2012

View full text Add to dashboard Cite

show abstract

“…On the other hand, we also recognized the mRNA downregulation of Prx II and VI in the organ of Corti after cisplatin exposure. Dahlan et al [24] showed that Prx II and VI of lymphocytes were downregulated in response to H2O2. Prx II is expressed exclusive in neurons [25], and its abundance in cochlea may contribute to protect neuronal structures against oxidative stimuli.…”

Section: Discussionmentioning

confidence: 99%

“…Prx II is expressed exclusive in neurons [25], and its abundance in cochlea may contribute to protect neuronal structures against oxidative stimuli. Although the exact molecular mechanism of Prx II down-regulation remains unclear, its down-regulation was reported to be produced by overoxidation induced by stimuli such as cisplatin or H2O2 [24]. Prx VI was also downregulated in response to stress stimuli in hepatocytes [26] or lens epithelial cells [27].…”

Section: Discussionmentioning

confidence: 99%

The role of peroxiredoxin I in cisplatin-induced ototoxicity

Tabuchi

Warabi

et al. 2017

Auris Nasus Larynx

View full text Add to dashboard Cite

“…In Malaysia, diabetes mellitus is diagnosed to be increased tremendously recently [31]. This matter has affected the quality of life in society as diabetic condition causes a lot of complications include cognitive impairment and DNA damage [17,[32][33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Tri-E® Prevents Cognitive Impairment and Deoxyribonucleic Acid Damage in Diabetes Mellitus

Asmara

Latif

Faisal

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The aim of the current study is to compare the difference of Tri-E ® and ATF potentials in reducing diabetic adverse event due to hyperglycemia that might cause the DNA damage and cognitive impairment indirectly. Methods: Diabetic model sample from Sprague Dawley was developed by combination of twice low-dose streptozotocin injection and high fat diet. The diabetic rat model was treated with Tri-E ® and ATF in different groups, control group were provided. The DNA was collected from the whole blood and DNA damage was measured using the comet assay method. While cognitive status was measured using Morris water-maze method. Result: Reduction of the DNA damage and improvement of cognitive function were observed in both ATF and Tri-E ® supplementations that elevated in diabetic. However, the DNA damage reduction by Tri-E ® was onefold higher compared to ATF supplementation. Conclusion: This study provided data that Tri-E ® has superior potential than ATF as a preventative agent to DNA damage and cognitive impairment in diabetes indirectly.

show abstract

Proteomic analysis reveals that treatment with tocotrienols reverses the effect of H2O2 exposure on peroxiredoxin expression in human lymphocytes from young and old individuals

Cited by 21 publications

References 40 publications

Dopaminergic therapies modulate the T‐CELL proteome of patients with Parkinson's disease

Dopaminergic therapies modulate the T‐CELL proteome of patients with Parkinson's disease

The role of peroxiredoxin I in cisplatin-induced ototoxicity

Tri-E® Prevents Cognitive Impairment and Deoxyribonucleic Acid Damage in Diabetes Mellitus

Contact Info

Product

Resources

About